|Awarded On||February 21, 2018|
|Title||Therapeutics Targeting Cancer-Associated HPV Replication|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Cheng-Ming Chiang|
|Cancer Sites||Cervix Uteri, Head and Neck|
Human papillomavirus (HPV)-induced cervical cancer is a leading cause of death in women. In addition, HPV is causally associated with some oral cancers developed via sexual contact and found mostly in men. Among >200 types of HPVs, only a dozen or so HPVs classified as “high-risk” are linked to cancer. Many “low-risk” HPVs only induce benign warts that rarely, if ever, progress to cancer. Recently, prophylactic vaccines that prevent up to nine major types of genital HPV infection (HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58) have become available and are recommended for vaccination of adolescent girls and boys. However, therapeutic agents that can “cure” HPV infection in the majority o...